Compare ARK Innovation ETF (ARKK) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs AstraZeneca plc — how do they compare? ARK Innovation ETF trades at $81.12, while AstraZeneca plc trades at $158.19 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while ARK Innovation ETF pays none, and ARK Innovation ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| ARKK | AZN | |
|---|---|---|
52-Week High | $92.50 | $209.48 |
52-Week Low | $63.52 | $147.06 |
Market Cap | — | $248.14B |
Sector | — | Health |
Enterprise Value | — | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.51, up 1.3% on the day, with technical indicators showing a bullish trend from moving averages but overbought short-term RSI. The ETF's performance remains challenged by high concentration in speculative growth stocks like Tesla and SpaceX, with no fundamental ratios provided. Recent news highlights Cathie Wood's continued bets on AI and space innovation amid criticism of fees and underperformance versus the S&P 500.
Outlook is cautious due to reliance on a few volatile holdings and premium fees; risks include growth deceleration and market sentiment shifts. Opportunities exist if disruptive bets pay off, but investor patience is required amid potential downside volatility.
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
